July 25, 2017, Paris, France – Dr. Landovitz, CHIPTS Co-Director, spoke on the “Enhancing the Impact of HIV Prevention” press conference regarding the findings of HPTN-077 at the 9th International AIDS Society Conference on HIV Science in Paris, France.
A previous phase 2a study of US males that used a dose of 800mL of cabotegrovir administered every 3 months did not consistently meet the pharmacokinetics standards. Due to this study, HPTN-077 studied not only a dosage of 800 mL in males and females administered every 3 months, but also a model dose of 600 mL every 8 weeks. HPTN-077 is a phase 2a study designed to measure the safety tolerability, acceptability, and pharmacokinetics of Cabotegravir.
Dr. Landovitz goes on to describe how HPTN-077 was conducted and its positive results, saying that they were “very supportive for moving forward into phase 3 efficacy studies with the 600 mL dose” noting that such a study was already in the field with HPTN-083 while HPTN-084 is currently in development.
The press conference included presentations from Jean-Michel Molina, Ayesha Kharsany, Andrew Grulich, Catherine Oldenburg, and moderator Linda-Gail Bekker and concluded with questions from the audience.
To see the entirety of Dr. Landovitz presentation, click on the photo below! Dr. Landovitz’s presentation begins at the the 7:05 mark.